Many people haven’t heard of Barrett’s Esophagus, but it’s a serious condition that can be a warning sign for a deadly cancer ...

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help ...

risk stratification in patients with and without a family history of Barrett's esophagus and/or esophageal cancer Presenter: Marcia (Mimi) Canto, M.D., MHS, professor of medicine at The Johns ...

Castle Biosciences, Inc, a leading diagnostics company improving health through innovative tests that guide patient care, announced it has signed a definitive agreement to acquire Capsulomics, Inc, ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Good afternoon and welcome to Castle Biosciences First Quarter 2025 ...

2:45-3:30 p.m. The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in ...

Robert D. Odze, MD noted that "These studies advance our understanding of the biological significance of WATS3D detected lesions and their risk of progression to cancer in Barrett's esophagus." ...

Castle Biosciences has signed an agreement to acquire GI health company Previse, which was developed by specialists at Johns Hopkins University School of Medicine in Baltimore. Previse is focused on ...